{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:05:32Z","timestamp":1775005532761,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305974\/2025-4"],"award-info":[{"award-number":["305974\/2025-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019693","name":"Universidade Federal da Fronteira Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["2024TR002502"],"award-info":[{"award-number":["2024TR002502"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["2025TR001686"],"award-info":[{"award-number":["2025TR001686"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["409156\/2024-8"],"award-info":[{"award-number":["409156\/2024-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019693","name":"Universidade Federal Da Fronteira Sul","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019693","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Urticaria is a skin lesion characterized by a central swelling area of varying sizes, usually surrounded by erythema and accompanied by itching or a burning sensation. Recurrence for at least six weeks characterizes chronic urticaria, a condition that has no cure, only treatment to minimize symptoms. The available pharmacological therapies show variable success and do not regulate the inflammatory balance of the skin in the long term. Therefore, it is essential to evaluate treatment possibilities to seek new symptom management approaches. In this regard, this study addresses the currently available therapies, linking the disease\u2019s pathophysiology with purinergic signaling to identify new therapeutic possibilities. In this respect, extracellular ATP is related to mast cells degranulation in the skin, which affects urticaria. Considering other dermatological diseases that present an inflammatory response, the purinergic receptor P2X7 is related to inflammation in several pathological skin conditions, such as psoriasis, dermatitis and pruritus. P2X7 engagement also contributes to ATP-mediated mast cell degranulation. Therefore, evaluating the expression of purinergic receptors in the skin of patients with chronic spontaneous urticaria, along with ATP levels in urticarial lesions, may help elucidate the therapeutic potential of targeting this purinergic pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Many patients are refractory to licensed therapies of H1antihistamines and omalizumab.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Cyclosporine and other immunosuppressants are studied for refractory patients.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Probiotics as adjuncts to antihistamines are studied to reduce symptoms.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>P2X7 receptor links to inflammatory skin diseases and may offer new therapy approach.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-026-02670-0","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:47:46Z","timestamp":1774997266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-3343","authenticated-orcid":false,"given":"Michelli","family":"Fontana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-9692","authenticated-orcid":false,"given":"J\u00falia Le\u00e3o Batista","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-9934","authenticated-orcid":false,"given":"Ge\u00f3rgia","family":"de Carvalho Braga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1080-654X","authenticated-orcid":false,"given":"Mauricio","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-7698","authenticated-orcid":false,"given":"Jo\u00e3o Carlos Menta","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-4980","authenticated-orcid":false,"given":"Margarete Dulce","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2670_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/all.15603","volume":"78","author":"A Kaplan","year":"2023","unstructured":"Kaplan A, Lebwohl M, Gim\u00e9nez- Arnau AM et al (2023) Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy 78:389\u2013401","journal-title":"Allergy"},{"key":"2670_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.joim.2020.05.004","volume":"18","author":"X Xiao","year":"2020","unstructured":"Xiao X, Zhang L, Shi Y et al (2020) Cupping therapy for patients with chronic urticaria: a systematic review and meta-analysis. J Integr Med 18:303\u2013312","journal-title":"J Integr Med"},{"key":"2670_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A et al (2024) Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet 404:393\u2013404","journal-title":"Lancet"},{"key":"2670_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jphs.2022.07.005","volume":"150","author":"I Matsuoka","year":"2022","unstructured":"Matsuoka I, Yoshida K, Ito M (2022) Purinergic regulation of mast cell function: P2X4 receptor-mediated enhancement of allergic responses. J Pharmacol Sci 150:94\u201399","journal-title":"J Pharmacol Sci"},{"key":"2670_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Latiff AHA, Abuzakouk M et al (2022) The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77:734\u2013766","journal-title":"Allergy"},{"key":"2670_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Munoz M, Asero R et al (2022) Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 149:1819\u20131831","journal-title":"J Allergy Clin Immunol"},{"key":"2670_CR7","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F et al (2017) The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 72:1821\u20132047","journal-title":"Allergy"},{"key":"2670_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100835","volume":"16","author":"MN Ghazanfar","year":"2023","unstructured":"Ghazanfar MN, S\u00f8rensen JA, Zhang D et al (2023) Occurrence and risk factors of mental disorders in patients with chronic urticaria. World Allergy Organ J 16:100835","journal-title":"World Allergy Organ J"},{"key":"2670_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12016-021-08886-x","volume":"61","author":"L He","year":"2021","unstructured":"He L, Yi W, Huang X et al (2021) Chronic urticaria: advances in understanding of the disease and clinical management. Clin Rev Allergy Immunol 61:424\u2013448","journal-title":"Clin Rev Allergy Immunol"},{"key":"2670_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110577","volume":"123","author":"W Bei","year":"2023","unstructured":"Bei W, Qian J, Zilu Q et al (2023) Comparing four immunosuppressive agents for chronic spontaneous urticaria-a network meta-analysis. Int Immunopharmacol 123:110577","journal-title":"Int Immunopharmacol"},{"key":"2670_CR11","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.62347\/XMFX3074","volume":"16","author":"J Xu","year":"2024","unstructured":"Xu J, Zhang X, Jiang Q-X et al (2024) Efficacy, safety, and serum cytokine modulation by olopatadine hydrochloride and desloratadine citrate disodium combination therapy in urticaria. Am J Transl Res 16:2501\u20132508","journal-title":"Am J Transl Res"},{"key":"2670_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879754","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Li J, Liu R et al (2022) The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol 13:879754","journal-title":"Front Immunol"},{"key":"2670_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147598","author":"K Gomu\u0142ka","year":"2024","unstructured":"Gomu\u0142ka K, Tota M, Laska J et al (2024) Serum concentration of IL-5 receptor (IL-5R) and associations with disease severity in patients with chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25147598","journal-title":"Int J Mol Sci"},{"key":"2670_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/imr.12632","volume":"282","author":"MK Church","year":"2018","unstructured":"Church MK, Kolkhir P, Metz M, Maurer M (2018) The role and relevance of mast cells in urticaria. Immunol Rev 282:232\u2013247","journal-title":"Immunol Rev"},{"key":"2670_CR15","doi-asserted-by":"publisher","unstructured":"Bernstein JA, Maurer M, Saini SS (2023) BTK signaling \u2014 a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol 1\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.008","DOI":"10.1016\/j.jaci.2023.12.008"},{"key":"2670_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2382774","author":"R Cai","year":"2024","unstructured":"Cai R, Zhou C, Tang R et al (2024) Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches. Gut Microbes. https:\/\/doi.org\/10.1080\/19490976.2024.2382774","journal-title":"Gut Microbes"},{"key":"2670_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","volume":"72","author":"D Elieh-Ali-Komi","year":"2023","unstructured":"Elieh-Ali-Komi D, Metz M, Kolkhir P et al (2023) Chronic urticaria and the pathogenic role of mast cells. Allergol Int 72:359\u2013368","journal-title":"Allergol Int"},{"key":"2670_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","volume":"139","author":"P Kolkhir","year":"2017","unstructured":"Kolkhir P, Church MK, Weller K et al (2017) Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 139:1772\u20131781","journal-title":"J Allergy Clin Immunol"},{"key":"2670_CR19","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s13555-023-00972-6","volume":"13","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Soares GB, Mahmoud O (2023) Current and emerging therapies for chronic spontaneous urticaria: a narrative review. Dermatol Ther (Heidelb) 13:1647\u20131660","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2670_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/CCID.S470160","volume":"17","author":"J Chen","year":"2024","unstructured":"Chen J, Ou S, Wu W et al (2024) Omalizumab in chronic spontaneous urticaria: a real-world study on effectiveness, safety and predictors of treatment outcome. Clin Cosmet Investig Dermatol 17:1799\u20131808","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2670_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4168\/aair.2021.13.4.521","volume":"13","author":"YM Ye","year":"2021","unstructured":"Ye YM (2021) Screening for autoimmune comorbidities in patients with chronic spontaneous urticaria: which tests to whom. Allergy Asthma Immunol Res 13:521\u2013523","journal-title":"Allergy Asthma Immunol Res"},{"key":"2670_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40257-023-00761-z","volume":"24","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Fox L, Siebenhaar F et al (2023) Stepping down treatment in chronic spontaneous urticaria: what we know and what we don\u2019t know. Am J Clin Dermatol 24:397\u2013404","journal-title":"Am J Clin Dermatol"},{"key":"2670_CR23","doi-asserted-by":"publisher","unstructured":"Badloe FMS, Grosber M, Ring J et al (2024) Treatment of acute urticaria: a systematic review. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.19904","DOI":"10.1111\/jdv.19904"},{"key":"2670_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.annemergmed.2017.03.006","volume":"71","author":"C Barniol","year":"2018","unstructured":"Barniol C, Dehours E, Mallet J et al (2018) Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial. Ann Emerg Med 71:125-131.e1","journal-title":"Ann Emerg Med"},{"key":"2670_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guill\u00e9n-Aguinaga","year":"2016","unstructured":"Guill\u00e9n-Aguinaga S, J\u00e1ureguiPresa I, Aguinaga-Ontoso E et al (2016) Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 175:1153\u20131165","journal-title":"Br J Dermatol"},{"key":"2670_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156814","volume":"185","author":"P Ji","year":"2025","unstructured":"Ji P, Chen H, Yang Y et al (2025) Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria. Cytokine 185:156814","journal-title":"Cytokine"},{"key":"2670_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.iac.2004.01.005","volume":"24","author":"JP Dice","year":"2004","unstructured":"Dice JP (2004) Physical urticaria. Immunol Allergy Clin North Am 24:225\u2013246","journal-title":"Immunol Allergy Clin North Am"},{"key":"2670_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.23822\/EurAnnACI.1764-1489.200","volume":"54","author":"N Atefi","year":"2022","unstructured":"Atefi N, Fallahpour M, Sharifi S et al (2022) Probiotic as an adjuvant therapy in chronic urticaria: a blinded randomized controlled clinical trial. Eur Ann Allergy Clin Immunol 54:123\u2013130","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2670_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ad.2023.02.015","volume":"114","author":"WK Budianti","year":"2023","unstructured":"Budianti WK, Mahri S, Almira D (2023) The role of adjuvant therapy in the management of chronic urticaria. Actas Dermosifiliogr 114:523\u2013530","journal-title":"Actas Dermosifiliogr"},{"key":"2670_CR30","unstructured":"U.S. Food and Drug Administration (2025) RHAPSIDO\u00ae (remibrutinib) - highlights of prescribing information. Nov Drug Approv 2025"},{"key":"2670_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M et al (2025) Remibrutinib in chronic spontaneous urticaria. N Engl J Med 392:984\u2013994","journal-title":"N Engl J Med"},{"key":"2670_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","volume":"143","author":"CEH Grattan","year":"2000","unstructured":"Grattan CEH, Donnell BFO, Francis DM et al (2000) Randomized double-blind study of cyclosporin in chronic \u201cidiopathic\u201d urticaria. Br J Dermatol 143:365\u2013373","journal-title":"Br J Dermatol"},{"key":"2670_CR33","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A et al (2022) Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 150:1498\u20131506","journal-title":"J Allergy Clin Immunol"},{"key":"2670_CR34","first-page":"1","volume":"15","author":"L Zhu","year":"2024","unstructured":"Zhu L, Jian X, Zhou B et al (2024) Gut microbiota facilitate chronic spontaneous urticaria. Nat Commun 15:1\u201317","journal-title":"Nat Commun"},{"key":"2670_CR35","first-page":"1","volume":"14","author":"YZ Shi","year":"2023","unstructured":"Shi YZ, Tao QF, Qin HY et al (2023) Causal relationship between gut microbiota and urticaria: a bidirectional two-sample mendelian randomization study. Front Microbiol 14:1\u20139","journal-title":"Front Microbiol"},{"key":"2670_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2022.1094737","volume":"12","author":"Z Luo","year":"2023","unstructured":"Luo Z, Jin Z, Tao X et al (2023) Combined microbiome and metabolome analysis of gut microbiota and metabolite interactions in chronic spontaneous urticaria. Front Cell Infect Microbiol 12:1\u201312","journal-title":"Front Cell Infect Microbiol"},{"key":"2670_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-021-00544-3","volume":"17","author":"X-D Bi","year":"2021","unstructured":"Bi X-D, Lu B-Z, Pan X-X et al (2021) Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo\u2011controlled trial. Allergy Asthma Clin Immunol 17:1\u20138","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2670_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0031-6997(25)06930-3","volume":"24","author":"G Burnstock","year":"1972","unstructured":"Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509\u2013581","journal-title":"Pharmacol Rev"},{"key":"2670_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1113\/expphysiol.2013.071951","volume":"99","author":"G Burnstock","year":"2014","unstructured":"Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99:16\u201334","journal-title":"Exp Physiol"},{"key":"2670_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1254\/jjp.78.113","volume":"78","author":"MP Abbracchio","year":"1998","unstructured":"Abbracchio MP, Burnstock G (1998) Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78:113\u2013145","journal-title":"Jpn J Pharmacol"},{"issue":"1","key":"2670_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2009.11","volume":"1","author":"G Burnstock","year":"2010","unstructured":"Burnstock G, Verkhratsky A (2010) Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis 1. https:\/\/doi.org\/10.1038\/cddis.2009.11","journal-title":"Cell Death Dis"},{"key":"2670_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115810","author":"L Chen","year":"2024","unstructured":"Chen L, Lei X, Mahnke K (2024) Adenosine and its receptors in the pathogenesis and treatment of inflammatory skin diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25115810","journal-title":"Int J Mol Sci"},{"key":"2670_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/jid.2011.344","volume":"132","author":"G Burnstock","year":"2012","unstructured":"Burnstock G, Knight GE, Greig AVH (2012) Purinergic signaling in healthy and diseased skin. J Invest Dermatol 132:526\u2013546","journal-title":"J Invest Dermatol"},{"key":"2670_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1216580","volume":"14","author":"ES Schulman","year":"2023","unstructured":"Schulman ES, Nishi H, Pelleg A (2023) Degranulation of human mast cells: modulation by P2 receptors\u2019 agonists. Front Immunol 14:1\u201311","journal-title":"Front Immunol"},{"key":"2670_CR45","first-page":"123","volume":"60","author":"JA Kiernan","year":"1975","unstructured":"Kiernan JA (1975) A pharmacological and histological investigation of the involvement of mast cells in cutaneous axon reflex vasodilatation. Q J Exp Physiol Cogn Med Sci 60:123\u2013130","journal-title":"Q J Exp Physiol Cogn Med Sci"},{"key":"2670_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF00561714","volume":"251","author":"JA Kiernan","year":"1974","unstructured":"Kiernan JA (1974) Action of adenosine triphosphate on mast cells in normal and denervated skin. Arch Dermatol Forsch 251:83\u201386","journal-title":"Arch Dermatol Forsch"},{"key":"2670_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031730","author":"B Salcman","year":"2024","unstructured":"Salcman B, Bahri R, West PW et al (2024) P2X7 receptor-induced human mast cell degranulation is enhanced by interleukin 33. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25031730","journal-title":"Int J Mol Sci"},{"key":"2670_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11302-012-9325-4","volume":"9","author":"Z-G Gao","year":"2013","unstructured":"Gao Z-G, Wei Q, Jayasekara MPS, Jacobson KA (2013) The role of P2Y14 and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal 9:31\u201340","journal-title":"Purinergic Signal"},{"key":"2670_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.7861\/clinmedicine.2-1-45","volume":"2","author":"G Burnstock","year":"2002","unstructured":"Burnstock G (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin Med (Northfield Il) 2:45\u201353","journal-title":"Clin Med (Northfield Il)"},{"key":"2670_CR50","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/sj.bjp.0702653","volume":"127","author":"CJ Dixon","year":"1999","unstructured":"Dixon CJ, Bowler WB, Littlewood-Evans A et al (1999) Regulation of epidermal homeostasis through P2Y2 receptors. Br J Pharmacol 127:1680\u20131686","journal-title":"Br J Pharmacol"},{"key":"2670_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110497","volume":"275","author":"S Liu","year":"2025","unstructured":"Liu S, Zhang Y, Li G, Liang S (2025) P2 purinergic signaling and pruritus. Neuropharmacology 275:110497","journal-title":"Neuropharmacology"},{"key":"2670_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-024-02481-1","author":"G de Carvalho Braga","year":"2024","unstructured":"de Carvalho Braga G, Francisco GR, Bagatini MD (2024) Current treatment of psoriasis triggered by cytokine storm and future immunomodulation strategies. J Mol Med. https:\/\/doi.org\/10.1007\/s00109-024-02481-1","journal-title":"J Mol Med"},{"key":"2670_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00638","volume":"8","author":"D Gentile","year":"2017","unstructured":"Gentile D, Lazzerini PE, Gamberucci A et al (2017) Searching novel therapeutic targets for scleroderma: P2X7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts. Front Pharmacol 8:1\u201313","journal-title":"Front Pharmacol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02670-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:02:58Z","timestamp":1775001778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02670-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2670"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02670-0","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}